Andrea F. Wainer - Sep 2, 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Sep 2, 2021
Transactions value $
-$807,750
Form type
4
Date filed
9/3/2021, 05:20 PM
Previous filing
Aug 19, 2021
Next filing
Nov 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $212K +4.5K +9.04% $47.00 54.3K Sep 2, 2021 Direct
transaction ABT Common shares without par value Options Exercise $192K +5K +9.21% $38.40 59.3K Sep 2, 2021 Direct
transaction ABT Common shares without par value Sale -$1.21M -9.5K -16.03% $127.50 49.8K Sep 2, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -4.5K -10.53% $0.00 38.2K Sep 2, 2021 Common Shares 4.5K $47.00 Direct F1
transaction ABT Option (right to buy) Options Exercise $0 -5K -14.29% $0.00 30K Sep 2, 2021 Common Shares 5K $38.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).